Insider trading

Period: 120 months Stock: LH Role: CEO × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

20 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

20 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

20 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

20 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
20 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
20 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

20 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
11 Aug 2026
Schechter Adam H President & CEO
Sold on a plan
$1.50M 4,669 at 320.37
4.4%
Planned (10b5-1)
11 May 2026
Schechter Adam H President & CEO
Sold on a plan
$1.50M 5,903 at 254.50
5.2%
Planned (10b5-1)
3 Mar 2026
Schechter Adam H President & CEO
Sold at will
$2.44M 8,705 at 279.96
9.7%
Not planned
11 Feb 2026
Schechter Adam H President & CEO
Sold on a plan
$1.50M 5,273 at 284.38
5.7%
Planned (10b5-1)
11 Nov 2025
Schechter Adam H President & CEO
Sold on a plan
$1.51M 5,745 at 262.75
6.2%
Planned (10b5-1)
11 Aug 2025
Schechter Adam H President & CEO
Sold on a plan
$1.51M 5,643 at 266.78
5.7%
Planned (10b5-1)
12 May 2025
Schechter Adam H President & CEO
Sold on a plan
$1.52M 6,105 at 248.73
5.8%
Planned (10b5-1)
11 Feb 2025
Schechter Adam H President & CEO
Sold on a plan
$1.50M 6,121 at 244.62
6.6%
Planned (10b5-1)
11 Nov 2024
Schechter Adam H President & CEO
Sold on a plan
$1.51M 6,189 at 243.47
6.6%
Planned (10b5-1)
19 May 2023
Kirchgraber Paul R CEO, Covance Drug Development
Sold at will
$932.71K 4,300 at 216.91
24.9%
Not planned
21 Feb 2023
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$2.00M 8,000 at 250.58
46.9%
6 May 2021
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$691.38K 2,500 at 276.55
24.2%
4 Nov 2020
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$321.20K 1,500 at 214.14
16.3%
28 Oct 2019
KING DAVID P President & CEO
Sold, plan not stated 3×
$4.99M 30,177 at 165.40
9.0%
30 May 2018
Gary M. Huff CEO, LabCorp Diagnostics
Sold, plan not stated
$293.82K 1,610 at 182.50
50.0%
23 May 2018
KING DAVID P President & CEO
Sold, plan not stated 2×
$8.76M 49,966 at 175.37
18.4%
23 Apr 2018
KING DAVID P President & CEO
Sold, plan not stated 2×
$8.30M 49,967 at 166.12
18.4%
23 Mar 2018
KING DAVID P President & CEO
Sold, plan not stated 4×
$8.23M 49,967 at 164.75
21.6%
6 Sep 2017
KING DAVID P President & CEO
Sold, plan not stated 2×
$7.01M 44,687 at 156.86
17.3%
5 Sep 2017
KING DAVID P President & CEO
Sold, plan not stated
$20.84M 132,713 at 157.06
38.3%
Showing 1–20 of 20.